SOM Biotech completes the recruitment process in the Phase IIb study of the treatment of chorea in Huntington’s disease

SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical study with SOM3355 as a treatment for Huntington’s chorea has been completed. After a a Phase IIa study where the Read more…

Prilenia Plans to Submit Marketing Authorization Application in the EU for Pridopidine in Huntington’s Disease

Prilenia announced today that they plan to submit a Marketing Authorization Application in the EU for the use of Pridopidine in the treatment of Huntington’s Disease. According to Dr. Michael Hayden, CEO of Prilenia “Pridopidine demonstrates consistent treatment benefits across independent measures that are important to patients and families. These Read more…

en_USEnglish